Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

This study is not yet recruiting - check back

A multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma.

Study Type:        Interventional

Study Design:        

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:        Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaCondition:  Peripheral T-Cell Lymphoma                                      

Intervention:  

Drug: Nivolumab  
Drug: Cabiralizumab                        

Phase:  Phase 2

External Link:  https://clinicaltrials.gov/ct2/show/NCT03927105